Gilead Sciences

4Q Revenues: $2.2 billion (+10%)

4Q Earnings: $665.1 million (+6%)

FY Revenues: $8.4 billion (+5%)

FY Earnings: $2.8 billion (-3%)

Comments: Antiviral product sales were up 9% to $1.9 billion in the quarter and up 8% to $7.1 billion for the year. Sales of Atripla were $863.3 million in the quarter (+11%) and $3.2 billion for the year (+10%). Sales of Truvada were $746.0 million in the quarter (+9%) and $2.9 billion for the year (+8%). Sales of Viread were flat at $190.9 million in the quarter and up 1% to $737.9 million for the year. Sales of Letairis were $78.7 million in the quarter (+23%) and $293.4 million for the year (+22%). Sales of Ranexa were up 23% in the quarter to $83.7 million and up 33% to $320.0 million for the year. Royalty, contract and other revenues from collaborations were $67.0 million in the quarter (-2%) and $283.0 million for the year (-49%), primarily due to lower Tamiflu royalties from Roche.